{"id":24658,"date":"2025-05-20T17:32:27","date_gmt":"2025-05-20T17:32:27","guid":{"rendered":"https:\/\/www.tun.com\/home\/?p=24658"},"modified":"2025-05-20T17:32:28","modified_gmt":"2025-05-20T17:32:28","slug":"revolutionary-non-opioid-painkiller-a-game-changer-in-pain-management","status":"publish","type":"post","link":"https:\/\/www.tun.com\/home\/revolutionary-non-opioid-painkiller-a-game-changer-in-pain-management\/","title":{"rendered":"Revolutionary Non-Opioid Painkiller: A Game Changer in Pain Management"},"content":{"rendered":"\n<div class=\"wp-block-group\"><div class=\"wp-block-group__inner-container is-layout-constrained wp-block-group-is-layout-constrained\">\n<div class=\"wp-block-uagb-blockquote uagb-block-e7eb3fc3 uagb-blockquote__skin-border uagb-blockquote__stack-img-none\"><blockquote class=\"uagb-blockquote\"><div class=\"uagb-blockquote__content\">Duke University unveils SBI-810, an experimental non-opioid painkiller offering powerful pain relief without addiction risks, marking a significant breakthrough in pain management.<\/div><footer><div class=\"uagb-blockquote__author-wrap uagb-blockquote__author-at-left\"><\/div><\/footer><\/blockquote><\/div>\n\n\n\n<div class=\"wp-block-group is-content-justification-space-between is-nowrap is-layout-flex wp-container-core-group-is-layout-b0ffac9c wp-block-group-is-layout-flex\"><div style=\"font-size:16px\" class=\"has-text-align-left wp-block-post-author\"><div class=\"wp-block-post-author__content\"><p class=\"wp-block-post-author__name\">The University Network<\/p><\/div><\/div>\n\n\n<div class=\"wp-block-uagb-social-share uagb-social-share__outer-wrap uagb-social-share__layout-horizontal uagb-block-ee584a31\">\n<div class=\"wp-block-uagb-social-share-child uagb-ss-repeater uagb-ss__wrapper uagb-block-ec619ce7\"><span class=\"uagb-ss__link\" data-href=\"https:\/\/www.facebook.com\/sharer.php?u=\" tabindex=\"0\" role=\"button\" aria-label=\"facebook\"><span class=\"uagb-ss__source-wrap\"><span class=\"uagb-ss__source-icon\"><svg xmlns=\"https:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 512 512\"><path d=\"M504 256C504 119 393 8 256 8S8 119 8 256c0 123.8 90.69 226.4 209.3 245V327.7h-63V256h63v-54.64c0-62.15 37-96.48 93.67-96.48 27.14 0 55.52 4.84 55.52 4.84v61h-31.28c-30.8 0-40.41 19.12-40.41 38.73V256h68.78l-11 71.69h-57.78V501C413.3 482.4 504 379.8 504 256z\"><\/path><\/svg><\/span><\/span><\/span><\/div>\n\n\n\n<div class=\"wp-block-uagb-social-share-child uagb-ss-repeater uagb-ss__wrapper uagb-block-32d99934\"><span class=\"uagb-ss__link\" data-href=\"https:\/\/twitter.com\/share?url=\" tabindex=\"0\" role=\"button\" aria-label=\"twitter\"><span class=\"uagb-ss__source-wrap\"><span class=\"uagb-ss__source-icon\"><svg xmlns=\"https:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 512 512\"><path d=\"M389.2 48h70.6L305.6 224.2 487 464H345L233.7 318.6 106.5 464H35.8L200.7 275.5 26.8 48H172.4L272.9 180.9 389.2 48zM364.4 421.8h39.1L151.1 88h-42L364.4 421.8z\"><\/path><\/svg><\/span><\/span><\/span><\/div>\n\n\n\n<div class=\"wp-block-uagb-social-share-child uagb-ss-repeater uagb-ss__wrapper uagb-block-1d136f14\"><span class=\"uagb-ss__link\" data-href=\"https:\/\/www.linkedin.com\/shareArticle?url=\" tabindex=\"0\" role=\"button\" aria-label=\"linkedin\"><span class=\"uagb-ss__source-wrap\"><span class=\"uagb-ss__source-icon\"><svg xmlns=\"https:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 448 512\"><path d=\"M416 32H31.9C14.3 32 0 46.5 0 64.3v383.4C0 465.5 14.3 480 31.9 480H416c17.6 0 32-14.5 32-32.3V64.3c0-17.8-14.4-32.3-32-32.3zM135.4 416H69V202.2h66.5V416zm-33.2-243c-21.3 0-38.5-17.3-38.5-38.5S80.9 96 102.2 96c21.2 0 38.5 17.3 38.5 38.5 0 21.3-17.2 38.5-38.5 38.5zm282.1 243h-66.4V312c0-24.8-.5-56.7-34.5-56.7-34.6 0-39.9 27-39.9 54.9V416h-66.4V202.2h63.7v29.2h.9c8.9-16.8 30.6-34.5 62.9-34.5 67.2 0 79.7 44.3 79.7 101.9V416z\"><\/path><\/svg><\/span><\/span><\/span><\/div>\n<\/div>\n<\/div>\n<\/div><\/div>\n\n\n\n<p class=\"wp-block-paragraph\">An experimental drug developed at Duke University School of Medicine could revolutionize pain management by delivering powerful relief without the addictive side effects of opioids.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The drug, known as SBI-810, represents a new class of compounds engineered to target specific nerve and spinal cord receptors. Unlike opioids which indiscriminately activate multiple cellular pathways leading to euphoria and addiction, SBI-810 precision-targets a single pain-relief pathway, sidestepping these common issues.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In a study <a href=\"https:\/\/www.cell.com\/cell\/abstract\/S0092-8674(25)00508-2\" target=\"_blank\" rel=\"noopener\" title=\"\">published<\/a> in Cell on May 19, Duke researchers reported that SBI-810 effectively alleviated pain on its own and enhanced the effectiveness of opioids at lower doses when used in combination, all while avoiding typical opioid side effects like constipation and tolerance buildup.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201cWhat makes this compound exciting is that it is both analgesic and non-opioid,\u201d senior author Ru-Rong Ji, Ph.D., a professor of anesthesiology and neurobiology at Duke and director of the Duke Anesthesiology Center for Translational Pain Medicine, said in a news release. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The drive for effective pain management alternatives couldn\u2019t be more urgent. Despite declining drug overdose deaths, more than 80,000 Americans die each year, predominantly from opioids. Additionally, chronic pain impacts one-third of the U.S. population. Therefore, a safer alternative like SBI-810 could be pivotal for both acute and chronic pain sufferers.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">SBI-810 functions by targeting the neurotensin receptor 1 in the brain and spinal cord. This receptor, when activated through a technique known as biased agonism, triggers the \u03b2-arrestin-2 signal specifically associated with pain relief, while avoiding other pathways that could lead to side effects and addiction.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201cThe receptor is expressed on sensory neurons and the brain and spinal cord,\u201d Ji added. \u201cIt\u2019s a promising target for treating acute and chronic pain.\u201d<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In preclinical trials involving mice, SBI-810 showed superior pain relief for conditions such as surgical incisions, bone fractures and nerve injuries. It also outperformed existing painkillers like opioids and gabapentin in certain scenarios, demonstrating greater effectiveness with fewer adverse effects.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The researchers highlighted that SBI-810, when compared to oliceridine, a newer opioid used in hospitals, performed better in some situations and showed fewer distress signs. Unlike opioids such as morphine, SBI-810 did not lead to tolerance after repeated use and avoided sedation or memory issues commonly associated with gabapentin.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The breakthrough underscores the compound&#8217;s dual action \u2014 on both peripheral and central nervous systems \u2014 suggesting it could provide balanced and potent pain relief while mitigating harm.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Duke University is fast-tracking SBI-810 toward human trials, backed by multiple patents and funding from the NIH and the Department of Defense. The collaborative effort included contributions from first authors Ran Guo and Ouyang Chen, among several others.<\/p>\n\n\n\n<div style=\"height:14px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Source:<\/strong> <a href=\"https:\/\/medschool.duke.edu\/news\/experimental-painkiller-could-outsmart-opioids-without-high\" target=\"_blank\" rel=\"noopener\" title=\"\">Duke University School of Medicine<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>An experimental drug developed at Duke University School of Medicine could revolutionize pain management by delivering powerful relief without the addictive side effects of opioids. The drug, known as SBI-810, represents a new class of compounds engineered to target specific nerve and spinal cord receptors. Unlike opioids which indiscriminately activate multiple cellular pathways leading to [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"single-no-separators","format":"standard","meta":{"_acf_changed":false,"_uag_custom_page_level_css":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[12],"tags":[74],"class_list":["post-24658","post","type-post","status-publish","format-standard","hentry","category-health","tag-duke-university"],"acf":[],"aioseo_notices":[],"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false},"uagb_author_info":{"display_name":"The University Network","author_link":"https:\/\/www.tun.com\/home\/author\/funky_junkie\/"},"uagb_comment_info":0,"uagb_excerpt":"An experimental drug developed at Duke University School of Medicine could revolutionize pain management by delivering powerful relief without the addictive side effects of opioids. The drug, known as SBI-810, represents a new class of compounds engineered to target specific nerve and spinal cord receptors. Unlike opioids which indiscriminately activate multiple cellular pathways leading to&hellip;","_links":{"self":[{"href":"https:\/\/www.tun.com\/home\/wp-json\/wp\/v2\/posts\/24658","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.tun.com\/home\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.tun.com\/home\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.tun.com\/home\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.tun.com\/home\/wp-json\/wp\/v2\/comments?post=24658"}],"version-history":[{"count":6,"href":"https:\/\/www.tun.com\/home\/wp-json\/wp\/v2\/posts\/24658\/revisions"}],"predecessor-version":[{"id":24667,"href":"https:\/\/www.tun.com\/home\/wp-json\/wp\/v2\/posts\/24658\/revisions\/24667"}],"wp:attachment":[{"href":"https:\/\/www.tun.com\/home\/wp-json\/wp\/v2\/media?parent=24658"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.tun.com\/home\/wp-json\/wp\/v2\/categories?post=24658"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.tun.com\/home\/wp-json\/wp\/v2\/tags?post=24658"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}